Literature DB >> 30050780

A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel.

Yi-Long Wu1, Chang-Li Wang2, Mei-Lin Liao3, Zhong-Zhen Guan4, Chen-Yan Gao5, Shun Lu3, Ming-Fang Zhao6, Jie Wang7, Xiao-Qing Liu8, Jin-Ji Yang1, Jun Liang9, Wei-Min Mao10, Bao-Hui Han3, Xu-Chao Zhang1, Yong Song11, Ji-Feng Feng12, Sheng-Lin Ma13, Gang Wu14, Cai-Cun Zhou15, Ke-Neng Chen16, Ying Cheng17, Yong He18, Chun Chen19, Qun Wang20, Ji-Zhen Lin21, Bo Zhu22, Yun-Peng Liu6, Yi Hu23, Gui-Bin Qiao24, Qing Zhou1, Qi-Bin Song25, Nan Wu16, Lin Wu26, Cheng Huang27, Xiao-Long Fu3, Jian-Ping Xiong28, Jie Hu20, Cheng-Ping Hu29, Jian-Hua Chang30, Qiong Zhao31, Jun Zhao16, Peng-Hui Zhou4, Zhi-Yong Ma32, Yuan Chen33, He-Long Zhang34, Fan Yang35, Jian-Jun Wang14, Yue-Yin Pan36, Xue-Ning Yang1, Yun Fan10, Zhe Liu37, Wen Fan30, Nong Yang26, Yan-Fang Guan38, Hao Sun1, Wen-Zhao Zhong1.   

Abstract

The notable clinical success of cancer immunotherapy using checkpoint blockade suggests that it is likely to form the foundation of curative therapy for many malignancies. However, checkpoint blockades do not achieve sustained clinical response in most patients and thus amounts of problems needed to be figured out. Regarding these challenges, the 2017 Chinese Lung Cancer Summit expert panel organized a forum on the 14th Chinese Lung Cancer Summit to formally discuss these controversies. Five consensuses finally were reached to guide the application of checkpoint blockades.

Entities:  

Keywords:  Lung cancer; consensus; immunotherapy

Year:  2018        PMID： 30050780      PMCID： PMC6037958          DOI： 10.21037/tlcr.2018.04.15

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


  32 in total

1.  Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells.

Authors:  V Bronte; M Wang; W W Overwijk; D R Surman; F Pericle; S A Rosenberg; N P Restifo
Journal:  J Immunol       Date:  1998-11-15       Impact factor: 5.422

2.  Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity.

Authors:  Stefani Spranger; Riyue Bao; Thomas F Gajewski
Journal:  Nature       Date:  2015-05-11       Impact factor: 49.962

3.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

4.  Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.

Authors:  Stéphane Champiat; Laurent Dercle; Samy Ammari; Christophe Massard; Antoine Hollebecque; Sophie Postel-Vinay; Nathalie Chaput; Alexander Eggermont; Aurélien Marabelle; Jean-Charles Soria; Charles Ferté
Journal:  Clin Cancer Res       Date:  2016-11-08       Impact factor: 12.531

5.  Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.

Authors:  Michael A Postow; Jason Chesney; Anna C Pavlick; Caroline Robert; Kenneth Grossmann; David McDermott; Gerald P Linette; Nicolas Meyer; Jeffrey K Giguere; Sanjiv S Agarwala; Montaser Shaheen; Marc S Ernstoff; David Minor; April K Salama; Matthew Taylor; Patrick A Ott; Linda M Rollin; Christine Horak; Paul Gagnier; Jedd D Wolchok; F Stephen Hodi
Journal:  N Engl J Med       Date:  2015-04-20       Impact factor: 91.245

6.  Cancer immunotherapy: moving beyond current vaccines.

Authors:  Steven A Rosenberg; James C Yang; Nicholas P Restifo
Journal:  Nat Med       Date:  2004-09       Impact factor: 53.440

7.  EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.

Authors:  Justin F Gainor; Alice T Shaw; Lecia V Sequist; Xiujun Fu; Christopher G Azzoli; Zofia Piotrowska; Tiffany G Huynh; Ling Zhao; Linnea Fulton; Katherine R Schultz; Emily Howe; Anna F Farago; Ryan J Sullivan; James R Stone; Subba Digumarthy; Teresa Moran; Aaron N Hata; Yukako Yagi; Beow Y Yeap; Jeffrey A Engelman; Mari Mino-Kenudson
Journal:  Clin Cancer Res       Date:  2016-05-25       Impact factor: 12.531

8.  MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy.

Authors:  Preeta Tyagi; Beloo Mirakhur
Journal:  Clin Lung Cancer       Date:  2009-09       Impact factor: 4.785

Review 9.  Regulatory T cells and Foxp3.

Authors:  Alexander Y Rudensky
Journal:  Immunol Rev       Date:  2011-05       Impact factor: 12.988
View more
  2 in total

Review 1.  Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China.

Authors:  Anwen Xiong; Jiali Wang; Caicun Zhou
Journal:  Front Oncol       Date:  2021-11-25       Impact factor: 6.244

2.  Synaptotagmin-7, a binding protein of P53, inhibits the senescence and promotes the tumorigenicity of lung cancer cells.

Authors:  Zhenhua Fei; Wei Gao; Raoying Xie; Ganzhu Feng; Xiaolin Chen; Yiyan Jiang
Journal:  Biosci Rep       Date:  2019-02-08       Impact factor: 3.840
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.